The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a tendering process for key components of its European Medicines Verification System (EMVS), a mechanism aimed at securing the legitimate supply chain against the emergence of counterfeit drugs. EFPIA is pulling out all the stops in order to prove that it has a credible and viable authentication system, before the European Commission is legally obliged to define one in 2014.
The driving force behind the EVMS is a requirement by the Falsified Medicines Directive, published on July 1, 2011, for...